Displaying drugs 15276 - 15300 of 15530 in total
MRT5005
MRT5005 is a human cystic fibrosis transmembrane conductance regulator (hCFTR) messenger RNA (mRNA) complexed with branched polyethyleneimine (bPEI).
Investigational
BVX-20
Investigational
OBI-888
Investigational
4A10
Investigational
M002
Investigational
NCATS-BL0746
Investigational
AMG-553
AMG-553 is an adoptive, anti-FLT3 chimeric antigen receptor T-cell therapy generated through transduction of autologous T-cells with a self-inactivating human immunodeficiency virus-1 based lentiviral vector.
Investigational
TCB-008
TCB-008 is an Allogeneic CD3+ T lymphocyte ex vivo expanded expressing the gamma delta T-cell receptor.
Investigational
Riliprubart
Investigational
EO-3021
Investigational
SMART101
SMART101 is an investigational cell therapy comprising human allogeneic CD34-CD7+ T cell progenitors that were cultured ex vivo.
Investigational
E59
E59 is a humanized IgG1 low affinity allergic reactivity inhibiting (LARI) monoclonal antibody. It was developed by Sixal Inc.
Investigational
SGN-B6A
SGN-B6A is a humanized immunoglobulin G1 anti-integrin beta-6 monoclonal antibody conjugated to monomethyl auristatin E.
Investigational
FLT201
FLT201 is a recombinant adeno-associated viral vector serotype S3 containing codon optimised expression cassette encoding human beta (β)-glucocerebrosidase variant 85 (GCasevar85)
Investigational
tgAAG-76
tgAAG-76 consists of a recombinant adeno-associated virus (serotype 2) (rAAV2) gene transfer agent expressing RPE65.
Investigational
GL-0719
Investigational
IBP-1118
Investigational
Saltikva
Investigational
HT-KIT
Investigational
VG161
VG161 is an oncolytic virus therapy under investigation for the treatment of cholangiocarcinoma.
Investigational
Emerfetamab
Emerfetamab is a bispecific T cell engager antibody construct with a half-life extension Fc moiety capable of binding to the neonatal Fc receptor.
Investigational
Displaying drugs 15276 - 15300 of 15530 in total